We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. OK, I agree | Cookies Policy

News

3

Noventure presents its pediatric range at the 51st ESPGHAN Annual Meeting in Geneva, 09-12 May 2018

As in previous years, Noventure has participated in the ESPGHAN Congress, held in Geneva, 09-12 May 2018. Pediatric gastroenterologists are a key target group for the recommendation and endorsement of new approaches to GI conditions in children. 4.627 delegates from 100 countries participated at the congress, and many of them approached Noventure´s stand to request information. Our innovative products intended for acute diarrhea (TASECTAN®, TASECTAN DUO® and XILAPLUS®) attracted a lot of interest from doctors.

Read more

Rhinosectan® Launched In Spain

We are pleased to announce the launch of Rhinosectan® in its first market, Spain. The product is commercialized under the brand Rinonet/Rhinosectan®, is distributed by Laboratorios SALVAT S.A.and has been available as 15 ml solution for intranasal application in pharmacies across Spain since May.

Read more

Noventure's Participation in 2018 EAU congress

For the third consecutive year, Noventure has participated in the annual congress of the EAU - European Association of Urology that took place in Copenhagen 17th – 19th March 2018 with about 11,000 participants, coming from 123 countries all over the world. During the Congress 273 scientific sessions included 2,656 presentations of cutting-edge urological updates presented by 1,830 international experts. Noventure participated in this congress with a 28 m2 stand to assess its presence in the urology field thanks to its medical device UTIPRO PLUS intended to control and prevent uncomplicated UTIs.

Read more

Let's meet in..

2019, Nov 05

CPhI 2019

Read more

2019, Nov 25

euroPLX 71

Read more

2019, Nov 28

PharmaVenue November 2019

Read more